Bausch Health Companies Inc. Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount
Bausch Health Companies Inc. (BHC) reported Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount of $0 for the 12-month period ending 2014-12-31, per its 10-K filed 2015-02-25.
Discontinued › Expense Statement › Income Tax
us-gaap:IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment · last filed 2015-02-25
- Bausch Health Companies Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2014 was $0.00.
- Bausch Health Companies Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2013 was $0.00, a 100.00% decline from fiscal 2012.
- Bausch Health Companies Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2012 was $3.20M.
- Bausch Health Companies Inc. effective income tax rate reconciliation, nondeductible expense, research and development, amount for fiscal 2011 was $0.00, a 100.00% decline from fiscal 2010.
| Period end | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month | Effective Income Tax Rate Reconciliation, Nondeductible Expense, Research and Development, Amount 12 month as first filed |
|---|---|---|
| 2014-12-31 | $0.00 10-K · filed 2015-02-25 | |
| 2013-12-31 | $0.00 10-K · filed 2015-02-25 | |
| 2012-12-31 | $3.20M 10-K · filed 2015-02-25 | $3.23M 10-K · filed 2013-02-28 |
| 2011-12-31 | $0.00 10-K · filed 2014-02-28 | |
| 2010-12-31 | $5.66M 10-K · filed 2013-02-28 | |
| 2009-12-31 | $21.06M 10-K · filed 2012-02-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Braveheart Bio, Inc. (BRVE) | United States | $2.106B | |
| PALVELLA THERAPEUTICS, INC. (PVLA) | United States | $2.105B | -35.55 |
| Trevi Therapeutics, Inc. (TRVI) | United States | $2.091B | -51.93 |
| OCULAR THERAPEUTIX, INC (OCUL) | United States | $2.159B | -7.15 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 |